Mélanie Paillard is an Inserm Associate Researcher in the IRIS (Ischemia-Reperfusion Injury Syndromes) team at CarMeN laboratory in Lyon. Her main research focus consists in pursuing a translational research for the development of new protective strategies targeting mitochondria during cardiometabolic diseases (including diabetic cardiomyopathy, HFpEF, myocardial infarction and stroke). Mélanie graduated from the Ecole Normale Supérieure of Lyon in 2008 and obtained her PhD in Physiology in 2012 from the University Claude Bernard Lyon1. Her PhD work focused on the role of some mitochondrial functions in the mechanisms of cardiomyocyte death during ischemia-reperfusion, notably the reticulum-mitochondria Ca2+ coupling (Paillard et al., Circulation 2013). Mélanie joined the MitoCare center of Pr Gyorgy Hajnoczky in 2013 (Philadelphia, USA), supported by postdoctoral fellowships from Fondation pour la Recherche Médicale and the American Heart Association. During her post-doctoral training, her research led to the discovery of the physio-pathological role of MICU1, a key regulator of the mitochondrial uniporter (Antony, Paillard et al., Nat Commun 2016; Paillard et al., Mol Cell 2018), for which she received the Young Bioenergeticist Award in 2017. Thanks to the combination of state-of-the-art techniques in live fluorescent imaging microscopy, proteomic analyses and in vivo mouse models up to the translational level in isolated human cardiomyocytes, she is now conducting a translational research focusing on mitochondrial Ca2+ regulation in the excitation-metabolic coupling, notably in diabetic HFpEF (Dia et al., Basic Res Cardiol 2020) and myocardial infarction (ANR MitoCaRe).